In other news….
COGNISANCE study calling Health and Social Care professionals
The COGNISANCE (Co-Designing Dementia Diagnosis and Post Diagnostic Care) study is a world-wide study led by the Universities of NSW, Sydney, and Wollongong under the lead of our ADNeT co-researchers Professor Henry Brodaty and Assoc. Professor Lee-Fay Low. COGNISANCE aims to improve the experience of dementia diagnosis and post-diagnostic support through developing toolkits, implemented through social marketing campaigns. Toolkits will provide structured information, tailored to enable health care practitioners to effectively enact national dementia guidelines around diagnostic and post-diagnostic support, and to empower people with dementia and their care partners to seek the support they require.
The study is currently conducting a survey to establish current Australian experiences of diagnosis and post-diagnostic support. If you are a health or social care professional, they would love you to participate. The survey is available online and will take about 15 – 20 minutes to complete. The survey is anonymous, but you can register your interest for further involvement in the project, if interested.
Your assistance will be greatly appreciated.
Biogen seeks approval for ADUCANUMAB as a treatment for dementia
Aducanumab is a disease modifying drug that slows the progression of Alzheimer’s disease. It works by removing amyloid plaques from the brain. Based on clinical data, Aducanumab has the potential to slow cognitive and functional decline and provide benefits to patients’ ability to manage their day to day activities.
Biogen has sought approval from the US FDA and has indicated they will also approach the TGA to seek approval for use in Australia in the treatment of Alzheimer’s disease.